{
    "clinical_study": {
        "@rank": "18180", 
        "arm_group": {
            "arm_group_label": "Reflux Patients", 
            "arm_group_type": "Experimental", 
            "description": "Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on\n      the production of inflammatory cytokines that lead to reflux esophagitis."
        }, 
        "brief_title": "The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Esophagitis", 
            "Reflux Esophagitis", 
            "Gastroesophageal Reflux Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Esophagitis", 
                "Esophagitis, Peptic", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "detailed_description": {
            "textblock": "Reflux esophagitis is thought to be caused by gastric acid that refluxes into the esophagus,\n      causing injury. Newer data suggest that reflux of gastric juice into the esophagus\n      stimulates HIF-2a, which increases production of inflammatory cytokines.  These cytokines\n      are thought to lead to reflux esophagitis. The investigators plan to study the relationship\n      of HIF-2a to inflammatory cytokines in patients with known gastroesophageal reflux disease\n      and reflux esophagitis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  U.S Veteran\n\n          -  History of Los Angeles Grade C erosive esophagitis\n\n        Exclusion Criteria:\n\n          -  Inability to provide informed consent\n\n          -  Esophageal varices\n\n          -  Warfarin use\n\n          -  Coagulopathy that precludes safe biopsy of the esophagus\n\n          -  Comorbidity that precludes safe participation in the study\n\n          -  Allergy to fluorescein sodium\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733810", 
            "org_study_id": "2R01DK063621-11", 
            "secondary_id": "R01DK063621"
        }, 
        "intervention": {
            "arm_group_label": "Reflux Patients", 
            "description": "Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.", 
            "intervention_name": "Cessation of Acid Suppressing Medications", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Esophagitis", 
            "Reflux esophagitis", 
            "Gastroesophageal reflux disease", 
            "Acid", 
            "Inflammation", 
            "Esophagus", 
            "Cytokines", 
            "Esophageal squamous cell", 
            "Reflux", 
            "Squamous epithelium"
        ], 
        "lastchanged_date": "February 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75216"
                    }, 
                    "name": "Dallas VA Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Stuart J. Spechler, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kerry B. Dunbar, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Rhonda Souza, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Kerry.Dunbar@va.gov", 
                    "last_name": "Kerry B. Dunbar, MD, MPH", 
                    "phone": "214-857-1603"
                }, 
                "contact_backup": {
                    "email": "Stuart.Spechler@va.gov", 
                    "last_name": "Stuart J Spechler, MD", 
                    "phone": "214-857-1603"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75216"
                    }, 
                    "name": "Dallas VA Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Ronda Souza, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Kerry B. Dunbar, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis", 
        "overall_contact": {
            "email": "Kerry.Dunbar@va.gov", 
            "last_name": "Kerry B. Dunbar, MD, PhD", 
            "phone": "214-857-1603"
        }, 
        "overall_contact_backup": {
            "email": "Stuart.Spechler@va.gov", 
            "last_name": "Stuart J. Spechler, MD", 
            "phone": "214-857-1603"
        }, 
        "overall_official": {
            "affiliation": "Dallas VA Medical Center", 
            "last_name": "Stuart J Spechler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "inflammation of the squamous esophageal mucosa will be measured at baseline and at 14 days", 
            "measure": "change in esophageal inflammation from baseline to 14 days", 
            "safety_issue": "No", 
            "time_frame": "day 0 and day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733810"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dallas VA Medical Center", 
            "investigator_full_name": "Stuart Spechler", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Amount of HIF-2a present will be measured at baseline and at 14 days", 
            "measure": "change in HIF-2a levels from baseline to 14 days", 
            "safety_issue": "No", 
            "time_frame": "day 0 and day 14"
        }, 
        "source": "Dallas VA Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Dallas VA Medical Center", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}